Non-Dilutive Financing Options: Pros, Cons, and How to Know Which One Is Right for You

Non-dilutive financing is not a single product—it is a menu of structures, each priced to a different risk profile and designed to solve a different problem. Asset-based lending monetizes the balance sheet. Cash flow lending leverages EBITDA. Mezzanine stretches total leverage for companies that have outgrown bank capacity. Revenue-based financing ties repayment to revenue performance. Venture debt extends runway for growth-stage companies backed by institutional equity. The mistake most CEOs and CFOs make is treating these as interchangeable—choosing the most familiar option rather than the most appropriate one.

Each instrument comes with a different underwriting logic, a different cost of capital, and a different set of trade-offs. Used correctly, any of them can be a strategic accelerant. Used incorrectly, they create cash flow drag, covenant friction, or structural mismatch that compounds over time.

This guide provides a working framework: what each instrument is, what it costs, who qualifies, and where it fits in a capital strategy.

The Non-Dilutive Financing Landscape

The five instruments below span the full range of company stage, asset profile, and capital need. They are not mutually exclusive—many capital structures layer two or more of them. The right starting point is understanding how each one underwrites risk.

• Asset-Based Lending (ABL): Revolving credit facility secured by AR, inventory, and equipment. Availability is determined by a borrowing base formula and fluctuates with the collateral pool. The natural home for working capital management and companies with strong balance sheets but inconsistent earnings.

• Cash Flow Loans: Term loan sized as a multiple of EBITDA. Purpose-built for profitable, asset-light companies that need patient, fixed capital for acquisitions, recapitalizations, or expansion. Available from banks, private credit funds, and SBIC vehicles.

• Mezzanine Financing: Subordinated, high-yield debt that pushes total leverage beyond what senior lenders will provide. Priced at 17–22% IRR, minimal amortization, and a small equity warrant. The instrument for companies maximizing non-dilutive capital on high-ROI transactions.

• Revenue-Based Financing (RBF): A capital advance repaid as a percentage of monthly revenue (typically 2–10%) until a payback cap of 1.2–1.6× is reached. Built for companies with strong, recurring top-line revenue but inconsistent or negative EBITDA. Faster to close and lighter to underwrite than EBITDA-based structures.

• Venture Debt: Non-dilutive debt sized relative to institutional equity raised (typically 30–60% of the most recent round) rather than EBITDA. Available to pre-profitable, venture-backed companies as a runway extender between equity rounds or a bridge to a valuation-enhancing milestone.

Asset-Based Lending (ABL)

What It Is

An Asset based lending facility is a revolving line of credit secured by a company’s liquid assets. Availability is not fixed at close—it is calculated continuously via a Borrowing Base (BB) formula that applies negotiated advance rates to eligible AR (70–90%), finished goods inventory (50–65%), and equipment at NOLV (40–60%). As customers pay invoices, collections sweep back against the drawn balance and replenish availability for future draws. The facility breathes with the operating cycle.

Because underwriting is anchored to asset quality rather than income statement performance, profitable EBITDA is not required. A manufacturer with $8M in eligible AR, $4M in finished goods, and $3M in equipment NOLV can access a $9.7M+ borrowing base regardless of whether the business is profitable. For companies with a timing mismatch—strong operations but cash locked in working capital—ABL resolves that friction without equity dilution.

The operational trade-off is monitoring. ABL lenders require a monthly Borrowing Base Certificate (BBC) and 1–4 collateral field exams per year. This is real administrative cost, but materially lighter than the quarterly data rooms required by traditional cash flow lenders.

Lending Parameters

Parameter	Details / Typical Range
Loan Amount	$0 – $100M+, scales with eligible asset base
Term & Structure	24–36 months, revolving; draw/repay/redraw freely
Eligibility	$1M+ annual revenue; positive EBITDA not required
Underwriting Basis	Collateral quality: AR collectability, inventory salability, equipment NOLV
Pricing	SOFR + 300–700 bps; interest on drawn balance only
Advance Rates	AR: 70–90% | Inventory (FG): 50–65% | Equipment (NOLV): 40–60%
Amortization	Revolving; no fixed principal payments
Covenants	Covenant-light; liquidity measure + senior leverage ≤2.5–3.0x
Time to Fund	15–30 days; no QoE required
Personal Guarantee	Not required for true corporate facilities

Cash Flow Loans

What It Is

Cash flow lending sizes borrowing capacity as a multiple of adjusted EBITDA—typically 2.0–3.0x for senior debt, up to 4.5x in a layered structure. Unlike ABL, which contracts and expands with the collateral pool, a cash flow term loan delivers a fixed amount at close: no borrowing base, no monthly recalculation, no risk of availability compressing at an inopportune moment.

The instrument is purpose-built for asset-light companies that cannot generate sufficient collateral for an ABL facility—services businesses, technology companies, professional firms, and distributors with lean balance sheets but durable EBITDA. It is also the standard vehicle for acquisition financing, where the target’s known EBITDA provides underwriting clarity that a greenfield initiative cannot.

The underwriting is heavier than ABL. Lenders require a Quality of Earnings (QoE) report to validate normalized EBITDA, 3 years of financial statements, forward projections, and a full data room. Closing typically runs 4–8 weeks. Financial covenants are harder: senior leverage caps of 2.0–3.0x and FCCR minimums of 1.1–1.4x are standard and non-springing.

Lending Parameters

Parameter	Details / Typical Range
Loan Amount	$2M – $50M+
Term & Structure	3–5 years, term loan; may include interest-only periods or back-loaded amortization
Eligibility	$5M+ annual revenue; $1M+ EBITDA; proven operational track record
Underwriting Basis	EBITDA stability, leverage & coverage ratios, management quality, industry risk
Pricing	SOFR + 300–800 bps; may include cash and PIK components
Amortization	Equal, back-loaded, interest-only period, or bullet—varies by lender
Covenants	Senior leverage: 2.0–3.0x; total leverage: 3.0–4.5x; FCCR: 1.1–1.4x
Time to Fund	4–8 weeks; QoE report required for non-personal-guarantee transactions
Typical Providers	Banks, private credit funds, SBIC funds, family offices

Mezzanine Financing

What It Is

Mezzanine debt is subordinated, high-yield capital that sits between senior secured debt and equity in the capital stack. It is, in essence, a “stretch” cash flow loan—structured to push total leverage to 4.0–5.0x EBITDA in situations where senior lenders cap out at 2.0–3.0x. For a company with $10M in EBITDA, that means access to $10–20M of incremental non-dilutive capital beyond the senior facility.

Mezzanine lenders are compensated for their subordinated risk through a high all-in return (typically a 17–22% IRR) built from three components: cash interest (10–13%), PIK interest that accrues to principal instead of being paid in cash (1–4%), and equity warrants representing 0–5% of exit value. PIK is the structural benefit: it defers cash outflow and frees operating capital during the high-investment phase of the business cycle.

The amortization profile is patient by design. Unlike a senior term loan with quarterly principal payments, mezzanine debt commonly requires minimal or no principal amortization for Years 1–4, with the full balance due as a bullet at Year 5. The trade-off is refinancing risk at maturity—which is why lenders underwrite both current EBITDA and Year 4–5 enterprise value durability, rather than just near-term cash flow coverage.

Lending Parameters

Parameter	Details / Typical Range
Loan Amount	$6M – $50M+
Term & Structure	Typically 5 years; bullet or back-loaded amortization
Eligibility	$3M+ EBITDA; established cash flow; no personal guarantee
Underwriting Basis	EBITDA stability, enterprise value, management’s ability to handle leverage
Pricing	Cash interest: 10–13% | PIK: 1–4% | Warrants: 0–5% | Target IRR: 17–22%
Amortization	Minimal/none in Years 1–4; bullet in Year 5
Covenants	Total leverage: 3.0–5.0x; FCCR: 1.1–1.4x; negative covenants on new debt, dividends, asset sales
Time to Fund	4–8 weeks; QoE required
Typical Providers	Private credit funds, SBIC funds, unitranche lenders, family offices

Revenue-Based Financing (RBF)

What It Is

Revenue-based financing converts a portion of future revenue into growth capital today. Instead of a traditional amortization schedule, repayment is a defined percentage of monthly revenue—typically 2–10%—until cumulative payments reach a contractual payback cap, most commonly 1.2–1.6× the original advance. Payments rise when revenue is strong and compress when it softens. The total dollars paid are capped; the timing is variable.

The defining feature is what RBF does not require: no EBITDA, no collateral, no hard assets. Lenders underwrite revenue predictability—consistency of top-line, customer diversification, churn, and growth trend—rather than balance sheet liquidation value. This makes RBF the primary instrument for asset-light, revenue-generating companies that cannot access ABL or cash flow structures: early-stage SaaS businesses, e-commerce platforms, services firms with recurring contracts, and any company where the revenue pattern is durable but EBITDA is not yet stable.

RBF is the fastest instrument in the stack to close (2–6 weeks) and carries the lightest covenant package. The cost, however, reflects the risk profile: effective APR typically lands in the mid-teens to high 20s depending on repayment speed and revenue consistency. It is also limited in scale—facilities rarely exceed $10M—making it a growth financing tool for smaller companies rather than a mid-market capital structure solution.

Lending Parameters

Parameter	Details / Typical Range
Loan Amount	$100K – $10M (not designed for mid-market scale)
Term & Structure	12–36 months; payback cap triggers termination
Eligibility	Small biz: $200K+ revenue, 6+ months operating. Institutional: $1M+ recurring revenue
Underwriting Basis	Revenue consistency, customer concentration, churn rate, growth trajectory
Pricing	Payback cap of 1.2–1.6× advance; effective APR mid-teens to high 20s
Amortization	2–10% of monthly revenue until payback cap is reached
Covenants	Light; revenue-based thresholds; no leverage or FCCR covenants
Security	Usually unsecured; some lenders file UCC all-assets lien; no PG for institutional
Time to Fund	2–3 weeks (small); 3–6 weeks (institutional)

Venture Debt

What It Is

Venture debt is non-dilutive financing designed specifically for companies that have raised institutional equity but want to extend runway or fund growth without issuing a new equity round. The critical structural difference from every other instrument on this list: sizing is based on equity raised, not EBITDA. A company that raised a $20M Series B can typically access $6–12M in venture debt (30–60% of the most recent round), even if it is pre-profitable.

Lenders underwrite three things: sponsor quality (the credibility and commitment of the VC or PE firm backing the company), revenue trajectory (growth rate, retention, burn rate), and the viability of the next milestone or equity round. EBITDA is not the underwriting anchor—but revenue consistency and a credible growth plan are non-negotiable. Companies that are burning cash with no path to payback do not qualify, regardless of who their investors are.

Venture debt typically structures interest-only periods of 6–24 months, followed by term amortization over 24–60 months. Warrants are common but modest. The all-in cost is lower than mezzanine (cash interest of 8–13%) and meaningfully lower than the implied cost of issuing equity at the company’s current valuation—which is precisely the economic rationale for using it. Lenders do not seek board seats; governance is limited to observer rights and financial reporting covenants.

Lending Parameters

Parameter	Details / Typical Range
Loan Amount	$500K – $50M+, typically sized at 30–60% of most recent equity round
Term & Structure	18–60 months; interest-only period of 6–24 months is common
Eligibility	Post-Series A through pre-IPO; institutional sponsor required; $3M+ revenue preferred
Underwriting Basis	Sponsor quality, revenue trajectory, burn rate, milestone credibility
Pricing	Cash interest: 8–13%; PIK in some deals; warrants possible
Amortization	Interest-only to start; then term amortization; can align with revenue milestones
Covenants	Covenant-light; performance covenants tied to revenue or growth metrics, not leverage ratios
Security	Lien on company assets; equity pledge; no personal guarantee
Time to Fund	4–6 weeks; lenders require meetings with major shareholders
Typical Providers	Pure-play venture debt firms, bank technology lending groups, private credit funds with venture arms

Pros & Cons by Instrument

The table below summarizes the structural advantages and limitations of each instrument. No single row tells the full story—the right instrument is always a function of the company’s asset profile, stage, profitability, and intended use of funds.

	ABL	Cash Flow	Mezzanine	RBF	Venture Debt
Best For	Asset-heavy companies with working capital cycles (manufacturers, distributors, retailers)	Profitable, asset-light companies funding acquisitions, recaps, or organic expansion	Established companies maximizing non-dilutive leverage on high-ROI transactions	Revenue-generating companies with inconsistent EBITDA; emerging growth stage	VC/PE-backed companies extending runway between equity rounds
Profitability Required?	No	Yes — $1M+ EBITDA minimum	Yes — $3M+ EBITDA; stable cash flows	No — revenue consistency is the driver	No — sponsor backing and revenue traction required
Loan Size	$0 – $100M+	$2M – $50M+	$6M – $50M+	$100K – $10M	$500K – $50M+
Pricing	SOFR + 300–700 bps	SOFR + 300–800 bps	IRR: 17–22% (cash + PIK + warrants)	Payback cap 1.2–1.6× (APR: mid-teens to high 20s)	8–13% cash interest; warrants possible
Time to Fund	15–30 days	4–8 weeks	4–8 weeks	2–6 weeks	4–6 weeks
QoE Required?	No	Yes (non-PG transactions)	Yes	No	No
Key Pros	✓ No profitability required ✓ Fastest close (15–30 days) ✓ Auto-scales with AR/inventory ✓ Covenant-light ✓ No PG on corporate facilities ✓ Stacks with other debt	✓ Fixed amount at close (no collateral shrinkage) ✓ Broad use of proceeds ✓ Larger facilities for profitable companies ✓ Patient capital (3–5 years) ✓ Acquisition-optimized structures ✓ Builds institutional relationships	✓ Pushes leverage to 4.0–5.0x EBITDA ✓ Bullet = max cash flow during loan ✓ PIK defers cash interest ✓ Minimal dilution vs. equity ✓ No board seats ✓ 5-year duration	✓ No collateral or profitability required ✓ Fastest available (2–6 weeks) ✓ Payments flex with revenue ✓ Minimal covenants ✓ No PG (institutional) ✓ Accessible at small company scale	✓ Available pre-profitability ✓ Sized vs. equity raised, not EBITDA ✓ Interest-only periods ✓ Extends runway without new dilution ✓ No board seats ✓ Lower cost than equity
Key Cons	✗ Requires tangible assets ✗ Monthly BBC reporting burden ✗ 1–4 field exams per year ✗ Availability fluctuates with collateral ✗ AR eligibility limitations (90-day, concentration)	✗ Requires consistent EBITDA ✗ QoE required (cost + time) ✗ 4–8 week timeline ✗ Hard financial covenants ✗ Full data room required	✗ Most expensive non-dilutive option ✗ Requires $3M+ EBITDA ✗ Bullet = refinancing risk at maturity ✗ Small equity warrant (0–5%) ✗ Intercreditor complexity with senior lender	✗ Highest effective APR ✗ Capped at ~$10M (not mid-market scale) ✗ Revenue sweep may limit cash control ✗ Not suitable for capital-intensive uses ✗ Repayment timeline is uncertain	✗ Requires institutional sponsor (no bootstrapped) ✗ Lenders need shareholder meetings ✗ Sizing capped by equity raised ✗ Poor fit without revenue traction ✗ More expensive than cash flow debt

Which One Is Right for You?

The instrument selection question is not about preference—it is about fit. A few diagnostic questions narrow the field quickly:

Do you have significant AR, inventory, or equipment on your balance sheet?

If yes, ABL is likely your most cost-effective starting point. The borrowing base will determine your capacity; everything else flows from there. ABL can be layered with a cash flow term loan or mezzanine tranche if the asset base alone is insufficient for your capital need.

Is your company profitable with $1M+ in EBITDA?

A cash flow loan is available to you. If EBITDA exceeds $3M, you can access mezzanine debt as well. The choice between them depends on your total leverage target: if the senior cash flow loan meets your capital need, stop there. If you need more leverage than senior lenders will provide—for an acquisition, a recapitalization, or a step-change growth initiative—mezzanine fills the gap without issuing equity.

Are you pre-profitable with strong, recurring revenue?

RBF is built for you. It underwrites revenue consistency rather than EBITDA, closes faster than any other instrument, and requires no collateral. If you have institutional sponsor backing, venture debt is also available—at lower effective cost and larger facility sizes than RBF can provide.

Have you raised institutional equity (Series A or later)?

Venture debt is purpose-built for your situation. It extends the runway on your existing equity round, is sized relative to capital raised rather than EBITDA, and does not require profitability. The economic rationale is straightforward: venture debt costs a fraction of what the next equity round will cost in dilution.

Are you funding an acquisition?

The answer depends on what you are acquiring. If the target is asset-heavy, an ABL facility can be built against the target’s balance sheet at close. If the target is asset-light but profitable, a cash flow term loan underwrites against combined EBITDA. If you need leverage beyond what senior lenders will provide, mezzanine fills the gap. Most mid-market acquisitions use a combination—and require intercreditor agreements to govern priority between lenders.

Why Accrefi

Selecting the right instrument is the first decision. Executing it well is the harder one.

Each of the instruments in this guide is negotiated, not standardized. Advance rates, eligibility definitions, covenant structures, PIK ratios, payback caps, and warrant sizes are all variables that move with the quality of the mandate and the strength of the lender relationship. A company that goes directly to a single lender will be underwritten on that lender’s terms. A company that runs a structured process across multiple lenders will see where the market actually clears.

Accrefi is a full-service debt advisory firm. We do not lend capital—we work exclusively for the borrower. Our network spans 500+ lenders across banks, private credit funds, SBIC vehicles, mezzanine providers, RBF firms, venture debt providers, and specialty lenders. Our team’s background in banking and commercial finance means we know how individual lenders underwrite, not just how they market themselves.

What that means in practice:

• We identify the right instrument(s) for your capital need and business profile before approaching the market.

• We prepare lender-ready materials: financial narratives, borrowing base analyses, EBITDA bridges, and projection packages that reduce underwriting friction and compress timelines.

• We run a competitive process, generate multiple term sheets, and give you the leverage to negotiate rather than accept the first offer.

• We manage the full execution from term sheet through closing—coordinating QoE providers, legal counsel, lender diligence requests, and intercreditor negotiations.

The result is broader market access, stronger terms, and a capital structure designed for the business you are building—not the one the lender finds easiest to underwrite.

Frequently Asked Questions

Can I use more than one of these instruments at the same time?

Yes—most mid-market capital structures layer two or more. ABL + cash flow term loan is common. Cash flow loan + mezzanine is standard for leveraged acquisitions. When two or more lenders are involved, an intercreditor agreement governs payment priority, enforcement rights, and standstill provisions. ABL typically holds the senior secured first-lien position.

Which instrument is cheapest?

ABL and senior cash flow loans are the lowest-cost options (SOFR + 300–800 bps). Venture debt is next (8–13% cash interest). Mezzanine is more expensive (17–22% IRR all-in). RBF is the most expensive on an effective APR basis (mid-teens to high 20s), but its cost is often misread because it is expressed as a payback cap rather than an interest rate. Cost should always be evaluated against the ROI of the intended use—an expensive instrument that funds a high-return acquisition may create more value than a cheap instrument that funds nothing.

Do any of these require a personal guarantee?

ABL, mezzanine, and institutional RBF facilities do not require personal guarantees on true corporate loans. Cash flow loans at smaller sizes (sub-$2M) or through SBA programs may include PG requirements. Venture debt does not require PGs. If a lender is requesting a personal guarantee on a mid-market facility, it is typically a sign of insufficient collateral or cash flow coverage—not standard market practice.

What is a Quality of Earnings (QoE) report and when do I need one?

A QoE is a third-party financial analysis that normalizes EBITDA—stripping out one-time costs, owner-related expenses, and non-recurring items to determine sustainable cash flow. Cash flow lenders and mezzanine providers require it for non-personal-guarantee transactions because they are underwriting repayment from EBITDA, not from collateral. ABL, RBF, and venture debt lenders generally do not require QoEs. Budget $30,000–$80,000+ and 2–4 weeks for QoE fieldwork depending on company complexity.

How long does each instrument take to close?

ABL closes in 15–30 days. RBF closes in 2–6 weeks. Cash flow loans and mezzanine close in 4–8 weeks. Venture debt closes in 4–6 weeks. Complex deals involving multiple lenders, intercreditor negotiations, or QoE fieldwork extend timelines. Plan for the longer end of the range if this is your first institutional credit facility.

My company is not profitable. What are my options?

ABL, RBF, and venture debt are all available to pre-profitable companies. ABL requires tangible assets. RBF requires recurring revenue. Venture debt requires institutional equity sponsorship. Mezzanine and cash flow loans require positive EBITDA—these are not available to loss-making companies regardless of revenue scale.

What is an intercreditor agreement and when do I need one?

An intercreditor agreement (ICA) is the legal contract between two or more lenders that governs payment priority, enforcement rights, and standstill periods in the event of a default. It is required any time two lenders hold security interests in the same collateral or business. Key provisions include payment blockage (the senior lender can halt subordinated payments during a default) and standstill (the junior lender agrees not to enforce remedies for a defined period). ICAs are standard, well-understood documents—but negotiating them requires experienced counsel.